L 697661 | L-69,7661 | L697661 | CAS#135525-78-9

MedKoo Cat#: 526982 | Name: L-697661

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-697661 is a reverse transcriptase inhibitor potentially for the treatment of HIV infection.

Chemical Structure

L-697661

CAS#135525-78-9

Theoretical Analysis

MedKoo Cat#: 526982

Name: L-697661

CAS#: 135525-78-9

Chemical Formula: C16H15Cl2N3O2

Exact Mass: 351.0541

Molecular Weight: 352.21

Elemental Analysis: C, 54.56; H, 4.29; Cl, 20.13; N, 11.93; O, 9.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

L-697661; L 697661; L697661; L-697,661; L 697,661; L697,661.

IUPAC/Chemical Name

3-(((4,7-dichlorobenzo[d]oxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one

InChi Key

WHFRDXVXYMGAJD-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H15Cl2N3O2/c1-3-9-6-12(16(22)20-8(9)2)19-7-13-21-14-10(17)4-5-11(18)15(14)23-13/h4-6,19H,3,7H2,1-2H3,(H,20,22)

SMILES Code

O=C1C(NCC2=NC3=C(Cl)C=CC(Cl)=C3O2)=CC(CC)=C(C)N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 352.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Perrin L, Rakik A, Yerly S, Baumberger C, Kinloch-de Loës S, Pechère M, Hirschel B. Combined therapy with zidovudine and L-697,661 in primary HIV infection. AIDS. 1996 Sep;10(11):1233-7. PubMed PMID: 8883585. 2: Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari F, Collier A, Kahn J. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 1;12(4):363-70. PubMed PMID: 8673545. 3: Kilby JM, Saag MS. Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. Adv Exp Med Biol. 1996;394:291-8. Review. PubMed PMID: 8815693. 4: Staszewski S, Massari FE, Kober A, Göhler R, Durr S, Anderson KW, Schneider CL, Waterbury JA, Bakshi KK, Taylor VI, et al. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis. 1995 May;171(5):1159-65. PubMed PMID: 7538547. 5: Fan N, Evans DB, Rank KB, Thomas RC, Tarpley WG, Sharma SK. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. FEBS Lett. 1995 Feb 13;359(2-3):233-8. PubMed PMID: 7532595. 6: Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med. 1993 Oct 7;329(15):1065-72. PubMed PMID: 7690462. 7: Davey RT Jr, Dewar RL, Reed GF, Vasudevachari MB, Polis MA, Kovacs JA, Falloon J, Walker RE, Masur H, Haneiwich SE, et al. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5608-12. PubMed PMID: 8516307; PubMed Central PMCID: PMC46770. 8: Harris PJ. Possible toxicity associated with L-697,661 administration in a patient with AIDS. AIDS. 1992 Jun;6(6):597-9. PubMed PMID: 1382453.